RaySearch Laboratories AB (publ), a company involved in software for radiation therapy, announced on Monday that Clinica El Rosario in Colombia is the first RaySearch customer in South America to go live with treatment planning system RayStation for Accuray's Radixact System.
The firm has also been awarded a contract by Clinica El Rosario for oncology information system, RayCare. The clinic operates two advanced linear accelerators, the Artiste from Siemens, which uses IMRT and IGRT, in addition to the region's first installation of the Radixact System from Accuray. Missing until now was suitably advanced software to get the best results from the hardware installed.
The installation includes clinical-class capabilities for 3D conformal planning, IMRT, physician review and contouring, multi-criteria optimisation, auto breast planning, fall-back and electron planning, and deformable registration. RayStation supports planning for Accuray's Radixact System; the treatment planning software was produced in collaboration with Accuray.
Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable
Medivir and Vetbiolix report positive results from VBX-1000 Proof-of-Concept clinical study
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
ELIAS Animal Health names new chief revenue officer
Innate Pharma reports preclinical efficacy of IPH45
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval